Article

BREAKING: One-Year Delay on ICD-10 to October 2014 Finalized

The federal government has finalized a one-year delay in the compliance deadline for the nationwide conversion to ICD-10 code sets. The delay, first proposed in April, will move the compliance deadline to Oct. 1, 2014.

Read the full story: http://tinyurl.com/9al4xja

Source: ModernHealthcare.com

HHS said the extra time would allow healthcare organizations—small organizations in particular—adequate time to get ready for the changeover.

Related Videos
John Michael O'Brien, PharmD, MPH
4 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
Richard J. Nowak, MD, MS, Yale School of Medicine
4 experts are featured in this series.
Naim Alkhouri, MD
Christine Funke, MD
Related Content
Image credit: Pharmacy_Karanov images - stock.adobe.com
April 25th 2025

SGLT-2s, GLP-1s, Finerenone Have Unique Benefits in CKD, Diabetes: Meta-Analysis

Giuliana Grossi
The findings highlight important differences between therapies in managing blood glucose, blood pressure, lipids, and adverse effects in this high-risk patient population.
managed care cast logo
April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD
On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Elderly woman holding her hands | Image credit: Evrymmnt - stock.adobe.com
April 25th 2025

Clinical, Real-World Data Support Importance of Tocilizumab for RA

AJMC Contributor
Tocilizumab has emerged as a key treatment for rheumatoid arthritis, showing efficacy, safety, and potential cardiovascular benefits in recent studies.
Managed Care Cast Thumbnail
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
NYOH’s Doyle on Joining OneOncology: What We Value the Most Is Culture
April 25th 2025

NYOH’s Doyle on Joining OneOncology: What We Value the Most Is Culture

Mary Caffrey
New York Oncology and Hematology becomes the 27th practice in OneOncology.
glp-1 Wegovy, semaglutide | Image credit: Patrick Bay Damsted - stock.adobe.com
April 25th 2025

Can Medicare Sustain Widespread Access to GLP-1 Therapies?

Skylar Jeremias
Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related health issues, but it also risks adding tens of billions in new costs, highlighting the need for smart policy strategies to ensure access, affordability, and long-term sustainability.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo